20/20 Biolabs Inc.

08/19/2026 | Press release | Distributed by Public on 08/19/2026 07:19

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 18, 2026, 20/20 Biolabs, Inc. (the "Company") held an annual meeting of stockholders of the Company (the "Annual Meeting") via live webcast. Holders of shares of the Company's common stock at the close of business on June 22, 2026 were entitled to vote at the Annual Meeting. As of such date, there were 12,251,198 shares of common stock outstanding and entitled to vote. A total of 4,256,837 shares of common stock were represented in person or by valid proxies at the Annual Meeting, constituting a quorum.

Stockholders voted on five proposals at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement, dated June 23, 2026, the relevant portions of which are incorporated herein by reference. The final results for the votes cast for each proposal are set forth below, except for proposal 3 (Charter Amendment). The Company did not receive sufficient votes with respect to proposal 3 at the Annual Meeting. Accordingly, in accordance with proposal 5, the Company adjourned the Annual Meeting with respect to proposal 3 until September 16, 2026 at 10:00 a.m. Eastern Time. All stockholders may attend the adjourned meeting by visiting the same webinar portal used for the Annual Meeting at https://edge.media-server.com/mmc/go/AIDX2026AGM.

Proposal 1: The Company's stockholders elected six directors to the Board of Directors of the Company to serve until the next annual meeting of stockholders of the Company or until such directors shall resign, be removed or otherwise leave office. The votes regarding this proposal were as follows:

Votes For Votes
Withheld
Broker
Non-Votes
Jonathan Cohen 2,733,310 89,806 1,433,721
John G. Compton, Ph.D. 2,668,095 155,021 1,433,721
Richard M. Cohen 2,647,263 175,853 1,433,721
Prasanth Reddy 2,653,831 169,285 1,433,721
John W. Rollins 2,652,712 170,404 1,433,721
Michael A. Ross, M.D. 2,667,412 155,704 1,433,721

Proposal 2: The Company's stockholders ratified the appointment of dbbmckennon as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows:

Votes For Votes Against Abstentions
4,105,584 132,421 18,832

Proposal 4: The Company's stockholders approved the Company's 2026 Equity Incentive Plan. The votes regarding this proposal were as follows:

Votes For Votes Against Abstentions Broker Non-Votes
2,183,335 573,931 65,850 1,433,721

Proposal 5: The Company's stockholders approved the adjournment of the Annual Meeting to a later date if necessary to solicit additional proxies if there are not sufficient votes to approve any of the foregoing proposals at the time of the Annual Meeting, or any adjournment or postponement thereof. The votes regarding this proposal were as follows:

Votes For Votes Against Abstentions
3,037,106 1,132,166 87,565
20/20 Biolabs Inc. published this content on August 19, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 19, 2026 at 13:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]